Catalent vs Lonza: CDMO Comparison

Side-by-side comparison of Catalent and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Catalent → 76.5
Somerset, NJ (now Novo Holdings)
Signal Score
76/100
Quality (FDA + GMP)
79/100
FDA inspections
10
— NAI / VAI / OAI
3 / 6 / 1
FDA warning letters
2
EMA GMP certificates (active)
14
MHRA GMP certificates (compliant)
16
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, CAR-T, Lentiviral, Plasmid DNA
Lonza → 78.2
Basel, Switzerland
Signal Score
78/100
Quality (FDA + GMP)
95/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
5
Clinical programs (matched)
1
Capacity
—
Modalities
AAV, Lentiviral, Cell Therapy, mRNA
How we score CDMOs →  ·  Compare other CDMOs →
Evaluating Catalent and Lonza for a program?
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.